Breaking News

C Ray Therapeutics Completes Series A+ Financing Round Exceeding $100M

Will further improve its core technology platforms, upgrade high-throughput screening capabilities for innovative RDC drugs, and more.

Author Image

By: Charlie Sternberg

Associate Editor

C Ray Therapeutics (Chengdu) Co., Ltd. has completed a Series A+ financing round exceeding $100 million co-led by Shenzhen Capital Group Co., Ltd.’s Manufacturing Transformation and Upgrading New Materials Fund (SCGC) and TaiLong Capital, with participation from several institutions and industry players including GL Ventures, 3SBio, Guanghua Wutong, and a well-known industrial investment institution. WinX Capital acted as the exclusive financial advisor for this transaction.   This achie...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters